Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry

INTRODUCTION: Eculizumab has transformed outcomes for patients with atypical hemolytic uremic syndrome (aHUS). Its efficacy and safety profile was well characterized in the clinical trial program. The long-term safety profile was not previously assessed or compared against nontreated patients in an...

Descripción completa

Detalles Bibliográficos
Autores principales: Rondeau, Eric, Cataland, Spero R., Al-Dakkak, Imad, Miller, Benjamin, Webb, Nicholas J.A., Landau, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933459/
https://www.ncbi.nlm.nih.gov/pubmed/31890998
http://dx.doi.org/10.1016/j.ekir.2019.07.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933459/
https://www.ncbi.nlm.nih.gov/pubmed/31890998
http://dx.doi.org/10.1016/j.ekir.2019.07.016

Ejemplares similares